145 related articles for article (PubMed ID: 35594544)
1. Genetic and pharmacological PARP inhibition reduces axonal degeneration in C. elegans models of ALS.
Tossing G; Livernoche R; Maios C; Bretonneau C; Labarre A; Parker JA
Hum Mol Genet; 2022 Sep; 31(19):3313-3324. PubMed ID: 35594544
[TBL] [Abstract][Full Text] [Related]
2. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.
McGurk L; Mojsilovic-Petrovic J; Van Deerlin VM; Shorter J; Kalb RG; Lee VM; Trojanowski JQ; Lee EB; Bonini NM
Acta Neuropathol Commun; 2018 Aug; 6(1):84. PubMed ID: 30157956
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-Ribosylation) in Age-Related Neurological Disease.
McGurk L; Rifai OM; Bonini NM
Trends Genet; 2019 Aug; 35(8):601-613. PubMed ID: 31182245
[TBL] [Abstract][Full Text] [Related]
4. PARkinson's: From cellular mechanisms to potential therapeutics.
Lengyel-Zhand Z; Puentes LN; Mach RH
Pharmacol Ther; 2022 Feb; 230():107968. PubMed ID: 34391789
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) metabolism analysis in the nematode Caenorhabditis elegans.
St-Laurent JF; Desnoyers S
Methods Mol Biol; 2011; 780():413-25. PubMed ID: 21870275
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization.
McGurk L; Gomes E; Guo L; Mojsilovic-Petrovic J; Tran V; Kalb RG; Shorter J; Bonini NM
Mol Cell; 2018 Sep; 71(5):703-717.e9. PubMed ID: 30100264
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
8. Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.
Park H; Kam TI; Dawson TM; Dawson VL
Int Rev Cell Mol Biol; 2020; 353():1-29. PubMed ID: 32381174
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
Chiarugi A; Moskowitz MA
J Neurochem; 2003 Apr; 85(2):306-17. PubMed ID: 12675907
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage.
Rulten SL; Rotheray A; Green RL; Grundy GJ; Moore DA; Gómez-Herreros F; Hafezparast M; Caldecott KW
Nucleic Acids Res; 2014 Jan; 42(1):307-14. PubMed ID: 24049082
[TBL] [Abstract][Full Text] [Related]
12. Inherited Retinal Degeneration: PARP-Dependent Activation of Calpain Requires CNG Channel Activity.
Yan J; Günter A; Das S; Mühlfriedel R; Michalakis S; Jiao K; Seeliger MW; Paquet-Durand F
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327647
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
14. Altered DNA damage response in Caenorhabditis elegans with impaired poly(ADP-ribose) glycohydrolases genes expression.
St-Laurent JF; Gagnon SN; Dequen F; Hardy I; Desnoyers S
DNA Repair (Amst); 2007 Mar; 6(3):329-43. PubMed ID: 17188026
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
16. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia.
Brown DG; Shorter J; Wobst HJ
Bioorg Med Chem Lett; 2020 Feb; 30(4):126942. PubMed ID: 31926785
[TBL] [Abstract][Full Text] [Related]
17. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
18. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
Liu C; Fang Y
Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
[TBL] [Abstract][Full Text] [Related]
19. A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease.
Ikenaka K; Tsukada Y; Giles AC; Arai T; Nakadera Y; Nakano S; Kawai K; Mochizuki H; Katsuno M; Sobue G; Mori I
Sci Rep; 2019 Jul; 9(1):10104. PubMed ID: 31300701
[TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
